Now Accepting Nominations
2025 Harrington Prize for Innovation in Medicine
September 11, 2024
OXFORD, UK and CLEVELAND, Ohio, US, 11th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the...
Continue Reading
February 14, 2023
Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading
February 14, 2023
Thylacine Biotherapeutics Inc. entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform. Continue Reading
February 10, 2023
Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading
February 08, 2023
In an international, multicenter, pivotal Phase 3 trial, a single under-the-skin injection of a biological drug given to patients within seven days of the onset of COVID-19 symptoms cut the likelihood they needed to be hospitalized in half. Continue Reading
January 27, 2023
Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. Continue Reading
January 24, 2023
A team led by investigators at Massachusetts General Hospital (MGH), including Marc Wein, MD, PhD, Massachusetts General Hospital, 2018 Harrington Scholar-Innovator, might lead to a new, more convenient drug for preventing and treating osteoporosis. Continue Reading
January 12, 2023
Dr. Christiane Wrann of Massachusetts General Hospital selected for research aimed at using the novel exercise hormone irisin to treat Alzheimer’s disease Continue Reading
November 22, 2022
Travis Dunckley, PhD, University of Arizona, 2016 ADDF-Harrington Scholar and team have developed a candidate drug they hope may successfully block the development or advancement of Alzheimer’s disease in Down syndrome patients. Continue Reading
November 17, 2022
Study led by University Hospitals and Case Western Reserve University team details a small-molecule drug that lowers cholesterol by 70% in animal models Continue Reading
October 19, 2022
PIC Therapeutics has closed a $35 million Series A financing round centered around the advancement of its lead asset, a novel therapeutic for advanced metastatic breast cancer. Continue Reading